Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape

Cancer Immunology, Immunotherapy

Volumn 57, Issue 6, 2008, Pages 823-831

  Smahel, Michal ^a   Tejklova, Pavla ^a   Smahelova, Jana ^a   Polakova, Ingrid ^a   Mackova, Jana ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

E7 oncogene; Epitope; Human papillomavirus; Tumor escape

Indexed keywords

EPITOPE; PROTEIN E7; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; DISEASE COURSE; DISEASE PREDISPOSITION; EMBRYO; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; WILD TYPE;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES; FEMALE; H-2 ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MUTATION; NEOPLASMS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, VIRAL; POINT MUTATION;

EID: 43349094561     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0418-9     Document Type: Article

References (40)

1. Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844-854
2. Bai XF, Liu J, Li O, Zheng P, Liu Y (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111:1487-1496
3. Bauer S, Heeg K, Wagner H, Lipford GB (1995) Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand J Immunol 42:317-323
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
5. Chen CA, Okayama H (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6:632-638
6. Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellstrom I, Hellstrom KE (1992) Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148:2617-2621
7. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE (1991) Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 88:110-114
8. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379-387
9. Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1:464-470
10. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249
11. He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146-161
12. Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178-186
13. Jainchill JL, Aaronson SA, Todaro GJ (1969) Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 4:549-553
14. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675-678
15. Keating PJ, Cromme FV, Duggan KM, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA, Stern PL (1995) Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405-411
16. Khammanivong V, Liu XS, Liu WJ, Rodda SJ, Leggatt GR, Tindle RW, Frazer IH, Fernando GJ (2003) Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol Cell Biol 81:1-7
17. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961-976
18. Lee KH, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM (1998) Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183-4194
19. Lichtig H, Algrisi M, Botzer LE, Abadi T, Verbitzky Y, Jackman A, Tommasino M, Zehbe I, Sherman L (2006) HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350:216-227
20. Lin KY, Guarnieri FG, Staveley OK, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26
21. Lipford GB, Bauer S, Wagner H, Heeg K (1995) Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84:298-303
22. Ljunggren HG, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels MT, Bastin J, Schumacher TN, Townsend A, Karre K (1990) Empty MHC class I molecules come out in the cold. Nature 346:476-480
23. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A (1996) Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69:364-368
24. Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89:213-228
25. Nasiell K, Roger V, Nasiell M (1986) Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 67:665-669
26. Nemeckova S, Stranska R, Subrtova J, Kutinova L, Otahal P, Hainz P, Maresova L, Sroller V, Hamsikova E, Vonka V (2002) Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface. Cancer Immunol Immunother 51:111-119
27. Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J (2000) Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11:97-133
28. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC (2004) Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78:8468-8476
29. Reche PA, Glutting JP, Reinherz EL (2002) Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 63:701-709
30. Reche PA, Glutting JP, Zhang H, Reinherz EL (2004) Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 56:405-419
31. Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112-120
32. Sadovnikova E, Zhu X, Collins SM, Zhou J, Vousden K, Crawford L, Beverley P, Stauss HJ (1994) Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 6:289-296
33. Scott M, Nakagawa M, Moscicki AB (2001) Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8:209-220
34. Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455-464
35. Smahel M, Pokorna D, Mackova J, Vlasak J (2004) Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 6:1092-1101
36. Smahel M, Sima P, Ludvikova V, Marinov I, Pokorna D, Vonka V (2003) Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21:1125-1136
37. Smahel M, Sima P, Ludvikova V, Vonka V (2001) Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281:231-238
38. Smahel M, Smahelova J, Tejklova P, Tachezy R, Marinov I (2005) Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein. Int J Oncol 27:731-742
39. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M (2003) Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 64:538-542
40. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342-350